BMS' Actinium-225 Drug Meets Phase III Endpoint in NETs
Bristol Myers Squibb's RYZ101 (actinium-225-DOTATATE) has met its primary progression-free survival endpoint in the Phase III ACTION-1 trial, according to AllSci. The study enrolled patients with SSTR-positive gastroenteropancreatic neuroendocrine tumors who had previously been treated with lutetium-177, marking what AllSci described as "a landmark trial for alpha-radiopharmaceuticals."
The result represents the first positive Phase III data for an alpha-emitting radiopharmaceutical in this patient population and establishes proof of concept for actinium-225 as a therapeutic isotope following failure of lutetium-177-based therapy.
Background on Alpha Emitters in Oncology
Actinium-225 emits alpha particles, which deliver high-energy radiation over a very short range—typically just a few cell diameters. This physical property allows alpha emitters to deposit significant cytotoxic energy directly into tumor cells while limiting damage to surrounding healthy tissue. In contrast, lutetium-177 emits beta particles, which travel farther and deposit energy over a longer path.
RYZ101 pairs actinium-225 with DOTATATE, a somatostatin receptor-targeting peptide widely used in neuroendocrine tumor therapy. The compound is designed to bind to SSTR-positive tumor cells and deliver localized alpha radiation.
Key Trial Details
- Trial name: ACTION-1
- Design: Phase III study in SSTR-positive gastroenteropancreatic neuroendocrine tumors
- Patient population: Previously treated with lutetium-177
- Primary endpoint: Progression-free survival (met)
- Isotope: Actinium-225
What It Means
The ACTION-1 success validates actinium-225 as a next-generation isotope for patients whose disease has progressed on lutetium-177 therapy. For nuclear medicine and radiopharmaceutical developers, the trial provides clinical evidence that alpha emitters can extend treatment options in neuroendocrine tumors beyond beta-emitting agents. Bristol Myers Squibb is expected to release detailed efficacy and safety data at an upcoming medical meeting.
Sources
Check Your Supplement Interactions
Use our AI-powered checker to analyze supplement safety and interactions.
Open Interaction Checker →Comments (0)
This article is for informational purposes only and does not constitute medical or investment advice. It was written with AI assistance from the sources listed above. Check the original sources before relying on any detail.